Literature DB >> 18793693

Flucloxacillin-induced liver injury.

Elise Andrews1, Ann K Daly.   

Abstract

Flucloxacillin is a common cause of drug-induced liver injury in Europe, affecting in the region of 8.5 in every 100,000 first time users of the drug. The mechanism by which the drug causes the liver injury is currently unknown but it is believed to be influenced by a combination of genetic and environmental factors. This review summarises what is currently known about the disposition of flucloxacillin in the liver, considers potential mechanisms by which flucloxacillin may cause the liver injury, and suggests candidate genes which could determine individual susceptibility to flucloxacillin-induced liver injury.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18793693     DOI： 10.1016/j.tox.2008.08.009

Source DB:  PubMed          Journal:  Toxicology        ISSN： 0300-483X            Impact factor:   4.221


  9 in total

1.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 2.  Drug-induced liver injury in older adults.

Authors:  Sarah J Mitchell; Sarah N Hilmer
Journal:  Ther Adv Drug Saf       Date:  2010-12

Review 3.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 4.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

5.  Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin.

Authors:  C-J Törnhage; G Brunlöf; S M Wallerstedt
Journal:  Drug Healthc Patient Saf       Date:  2009-03-31

Review 6.  New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.

Authors:  Munir Pirmohamed; David A Ostrov; B Kevin Park
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

7.  Penicillinase-resistant antibiotics induce non-immune-mediated cholestasis through HSP27 activation associated with PKC/P38 and PI3K/AKT signaling pathways.

Authors:  Audrey Burban; Ahmad Sharanek; Romain Hüe; Marion Gay; Sylvain Routier; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2017-05-12       Impact factor: 4.379

8.  Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.

Authors:  Kevin Wing; Krishnan Bhaskaran; Louise Pealing; Adrian Root; Liam Smeeth; Tjeerd P van Staa; Olaf H Klungel; Robert F Reynolds; Ian Douglas
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

9.  Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole.

Authors:  Stefan J Dekker; Floor Dohmen; Nico P E Vermeulen; Jan N M Commandeur
Journal:  Br J Pharmacol       Date:  2018-12-26       Impact factor: 8.739
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.